Symptomatic therapy in multiple sclerosis: Big pharma should do more-YES
Mult Scler
.
2015 Jul;21(8):980-2.
doi: 10.1177/1352458515588974.
Epub 2015 Jun 17.
Authors
Aksel Siva
1
,
Orhun Kantarci
2
Affiliations
1
Department of Neurology, Cerrahpasa School of Medicine, Istanbul University, Cerrahpasa, Turkey akselsiva@gmail.com.
2
Mayo Clinic Center for Multiple Sclerosis and CNS Demyelinating Diseases, Department of Neurology, Mayo Clinic College of Medicine, USA.
PMID:
26084347
DOI:
10.1177/1352458515588974
No abstract available
MeSH terms
Cognition Disorders / etiology
Cognition Disorders / psychology
Drug Industry / trends*
Humans
Multiple Sclerosis / complications
Multiple Sclerosis / drug therapy*
Multiple Sclerosis / psychology